EMAIL-HF: Can Digital Strategies Shorten the Path from Scientific Evidence to Clinical Practice in Heart Failure?
Abstract
A substantial gap persists between scientific evidence and clinical practice in heart failure (HF). Digital solutions have emerged as promising strategies to accelerate the implementation of evidence-based therapies. This mini-review examines the results of the EMAIL-HF study, a registry-based, randomized, controlled, parallel-group clinical trial conducted in Denmark that included patients aged 20 years or older with a diagnosis of HF irrespective of left ventricular ejection fraction, who were not receiving SGLT2 inhibitors (SGLT2i). Participants were randomized to usual care or a digital strategy consisting of an e-mailed letter with information on SGLT2i, followed by contact with an HF specialist. The primary endpoint was the proportion of patients redeeming a prescription for dapagliflozin or empagliflozin within 6 months of randomization and the secondary endpoint was a composite of time to first HF hospitalization or death from any cause. The digital strategy significantly increased SGLT2i initiation within 6 months, although no difference in HF hospitalization or all-cause mortality was observed during the 24-month follow-up. Whether these strategies can translate modest improvements in treatment uptake into sustained, scalable, and cost-effective gains across diverse healthcare systems remains uncertain.
Related
- Comparative and synergistic effects of digital devices and Child Life services in pediatric clinical practice: a systematic review
- From Global Evidence to Saudi Practice: A Structured Evidence Map of the Diagnosis, Molecular Targets, and Therapeutic Strategies of Multiple Sclerosis in the Kingdom of Saudi Arabia.
- Clinical practice and optimization strategies for comprehensive nutritional support in gastric cancer patients
- Translating large-core thrombectomy evidence into clinical practice
- Digital Twins in Oncology: From Multimodal Data Integration to Precision Clinical Practice.
BibTeX
@article{albuquerque2026emailhf,
title = {{EMAIL-HF: Can Digital Strategies Shorten the Path from Scientific Evidence to Clinical Practice in Heart Failure?}},
author = {Monica T A Albuquerque and Patricia O Guimaraes and Caio a M Tavares and Vagner Madrini and Eduardo B Martins and Kalliopi Keramida and Dike Ojji and Kaveh Hosseini and Luca Monzo and Francesca Musella and Yasuhiko Sakata and Mario Enrico Canonico and Tamas Alexy and Jan Biegus and Savina Nodari and Andrew Ambrosy and Mitja Lainscak},
journal = {Heart Failure Reviews},
year = {2026},
month = nov,
doi = {10.1007/s10741-026-10691-7},
url = {https://hal.univ-lorraine.fr/hal-05857836v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - EMAIL-HF: Can Digital Strategies Shorten the Path from Scientific Evidence to Clinical Practice in Heart Failure?
AU - Monica T A Albuquerque
AU - Patricia O Guimaraes
AU - Caio a M Tavares
AU - Vagner Madrini
AU - Eduardo B Martins
AU - Kalliopi Keramida
AU - Dike Ojji
AU - Kaveh Hosseini
AU - Luca Monzo
AU - Francesca Musella
AU - Yasuhiko Sakata
AU - Mario Enrico Canonico
AU - Tamas Alexy
AU - Jan Biegus
AU - Savina Nodari
AU - Andrew Ambrosy
AU - Mitja Lainscak
PY - 2026
DA - 2026/11/07
JO - Heart Failure Reviews
DO - 10.1007/s10741-026-10691-7
UR - https://hal.univ-lorraine.fr/hal-05857836v1
AB - A substantial gap persists between scientific evidence and clinical practice in heart failure (HF). Digital solutions have emerged as promising strategies to accelerate the implementation of evidence-based therapies. This mini-review examines the results of the EMAIL-HF study, a registry-based, randomized, controlled, parallel-group clinical trial conducted in Denmark that included patients aged 20 years or older with a diagnosis of HF irrespective of left ventricular ejection fraction, who were not receiving SGLT2 inhibitors (SGLT2i). Participants were randomized to usual care or a digital strategy consisting of an e-mailed letter with information on SGLT2i, followed by contact with an HF specialist. The primary endpoint was the proportion of patients redeeming a prescription for dapagliflozin or empagliflozin within 6 months of randomization and the secondary endpoint was a composite of time to first HF hospitalization or death from any cause. The digital strategy significantly increased SGLT2i initiation within 6 months, although no difference in HF hospitalization or all-cause mortality was observed during the 24-month follow-up. Whether these strategies can translate modest improvements in treatment uptake into sustained, scalable, and cost-effective gains across diverse healthcare systems remains uncertain.
SN - 1382-4147
SN - 1573-7322
ER -